Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04735263 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

Study acronym: DELPHI
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 1, 2023 to Apr 1, 2027
    • Study completion date: Jan 1, 2024 to Jan 1, 2028
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 15, 2021 to Feb 4, 2021
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT
Trial Details
NCT Number NCT04735263
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions
(from sponsor)		 Age-related Macular Degeneration
Related terms Macular Degeneration
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov